UNSPSC 51282913: Difloxacin

This classification denotes a quinolone antibiotic with the molecular formula C21H19F2N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5Z7OO9FNFD, chemically known as 6-fluoro-1-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid but generally known as difloxacin, which bears US NIH Compound Identifier 56206. The term DIFLOXACIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27).

UNSPSC 51282913 Difloxacin is a Commodity code that nominally specifies a single veterinary antibiotic product, but recent state and local procurement activity under this code shows little alignment with that narrow specification. The recent opportunities posted under 51282913 span naloxone and drug deactivation systems for community health, direct-to-manufacturer prescription programs, medical and first aid supplies for fire rescue, and generic pharmaceuticals distributed through cooperative purchasing — none of which are difloxacin or directly related to veterinary antimicrobials. This mismatch suggests either broad miscoding by issuing bodies, or that the code has been repurposed in practice to capture human-health pharmaceutical and medical-supply procurement more broadly.

Issuing bodies soliciting under this code include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal purchasing departments (City of Tampa), and state-led cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local members across participating jurisdictions including Oregon). Recent activity spans Florida, Texas, and Minnesota, with the Minnesota MMCAP cooperative purchasing mechanism representing multi-state and multi-local government participation. Representative recent opportunities include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems (IFB, due July 26, 2026 per the corrected posting), the Texas HHS RFI HHS0017013 for direct-to-manufacturer prescription programs (RFI, response deadline April 3, 2026), the City of Tampa's IFB 26P00145 for medical and first aid supplies for fire rescue with an estimated contract value of $700,000 and SLBE set-aside (IFB, due March 13, 2026), and MMCAP's S1070000015802 for generic multi-source pharmaceuticals and OTC products (RFP, proposals due March 26, 2026). The Tampa solicitation is designated a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount not to exceed $10,000.